Olon has recently announced the acquisition of HuvePharma Italia Srl and its Garessio plant. Could you start by telling us what the primary objective of this acquisition is?
The main goal of acquiring HuvePharma Italia Srl is to significantly boost our overall production capacity, particularly in the development and production of active pharmaceutical ingredients (APIs). By integrating the Garessio plant into our network, we plan to revive and fully leverage its production potential, which aligns with our broader strategy of expanding our footprint in the global API market.
How does this acquisition align with Olon’s broader growth and expansion strategy?
Since its inception, Olon has pursued a consistent strategy of growth, consolidation, and expansion, both organically and through strategic acquisitions. The expertise of the companies we acquire, like HuvePharma Italia, enriches our offerings and enhances our competitiveness. This acquisition is a perfect example of that approach—by expanding our production capacity, we’re reinforcing our presence in key markets and advancing our long-term business objectives.
The Garessio plant has been noted for its technological advancements. Could you elaborate on the specific technologies and production capabilities that this facility brings to Olon?
The Garessio plant is indeed a state-of-the-art facility. It features advanced production lines, most of which are fully automated, and has pioneered the production of an important antimalarial product using advanced photo-oxidation technology. Additionally, the plant has developed capabilities in the manufacture of nanoparticles, which positions us well to meet the growing demand for cutting-edge pharmaceutical ingredients.
How does Olon plan to integrate HuvePharma Italia’s assets, facilities, and workforce into its existing operations?
Integration is key to our strategy. We plan to incorporate HuvePharma Italia’s assets, facilities, and workforce entirely into Olon’s operations. This includes the full operational integration of the Garessio site, ensuring that its production capabilities are maximized. Our approach has always been to value and build upon the strengths of the companies we acquire, and this will be no different.
Can you explain the role of Olon Biotech within the Olon Group and how it contributes to your overall service offerings?
Olon Biotech is a specialized division within the Olon Group that leverages cross-functional support from all corporate functions, including R&D, Marketing & Sales, Operations, Procurement, Regulatory, and Quality. It focuses on providing Contract Development and Manufacturing Services (CDMO) and developing, manufacturing, and selling Proprietary Products (PP). This division plays a crucial role in broadening our service offerings and ensuring we remain at the forefront of innovation in the biotech and pharmaceutical industries.
Finally, what do you believe are the key strengths of the Olon Group that have made it a leader in the global API market?
Olon’s strengths lie in our deep expertise in API development, our broad technological capabilities, and our commitment to the highest safety, quality, and environmental standards.
With a global network of 14 manufacturing sites and 9 R&D centres, we are well-positioned to help our clients successfully bring their molecules to market. Our ability to integrate chemical synthesis with biological processes, combined with our reputation as a reliable partner, makes us a leader in the API industry.
